Navigation Links
Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
Date:9/16/2008

SAN DIEGO, Sept. 16 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has secured a new credit facility through City National Bank to provide for additional capital investment in its newly constructed cGMP manufacturing plant. Althea intends to begin offering commercial manufacturing services in the fourth quarter of this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

"We are pleased to report the acquisition of this credit facility with City National Bank which will finance equipment for our recently constructed 30,000 SF cGMP commercial-scale manufacturing building. With truly state-of- the-art equipment, significant production capacities for biotech drugs and filling of finished drug products at the 100,000 unit batch size, this will enable Althea to advance to the next level as a major contract manufacturer. We look forward to working closely with the City National Bank team and are pleased with the attention and emphasis they have invested to this relationship," stated Dr. Magda Marquet, President and Co-CEO of Althea Technologies.

According to Gary Gilmore, Althea's CFO, the credit facility provides for $12 million of working capital and equipment financing for the new facilities.

Stephen Cusato, senior vice president and manager of City National Bank's Commercial Banking Services Office in San Diego, added, "We're excited to offer the bank's resources and our team's expertise to support Althea's expansion into commercial-scale manufacturing. We view this as the first step in a long-term relationship."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling. For more information, visit http://www.altheatech.com.

About City National Bank

City National Bank is the wholly owned subsidiary of City National Corporation (NYSE: CYN). It is backed by $16.3 billion in total assets, and provides banking, investment and trust services through 62 offices, including 15 full-service regional centers, in Southern California, the San Francisco Bay Area, Nevada and New York City. The company and its eight majority-owned investment affiliates manage or administer $53.5 billion in client investment assets, including $34 billion under direct management.

For more information about City National, visit the company's Website at http://www.cnb.com.

Contact:

Althea Technologies, Inc.

R. Gary Gilmore

Chief Financial Officer

(858) 882-0200

ggilmore@altheatech.com


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HealthEast Care System Selects Concuitys ClearContracts to Increase Contract Analysis and Negotiation Capabilities and Improve Revenue Cycle Management
2. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
3. Neptune Technologies decided not to re-price options
4. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
7. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
8. Anthill Technologies Announces Agreement With Zafgen
9. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
10. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
11. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial ... Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, ...
Breaking Biology Technology:
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):